Skip to content
Axcess News – Lifestyle
Author:
ORIC Pharmaceuticals
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
March 31, 2026
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
March 27, 2026
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
March 17, 2026
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 7, 2026
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
March 5, 2026
←
Previous Page
1
2